Get the Stockscreener App
14.63
0.86%
-0.1727
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $14.63, with a volume of 206.01K.
It is down -0.86% in the last 24 hours and down -6.29% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$14.80
Open:
$15.16
24h Volume:
206.01K
Relative Volume:
0.25
Market Cap:
$2.43B
Revenue:
$3.47B
Net Income/Loss:
$668.83M
P/E Ratio:
3.9381
EPS:
3.7138
Net Cash Flow:
$253.46M
1W Performance:
-2.40%
1M Performance:
-6.29%
6M Performance:
-2.47%
1Y Performance:
+14.13%
1-Day Range:
$14.52
$15.31
1-Week Range:
$14.52
$15.31
52-Week Range:
$12.87
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
ADR, GDR Listings of Indian companies - Goodreturns
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading - MSN
Infosys, Wipro ADRs down 3% on NYSE after Q2 results even as S&P, Dow drift near record-highs | Stock Market News - Mint
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Saudi Arabia Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire Inc.
Haryana Elections 2024: Capt. Abhimanyu, Savitri Jindal among wealthiest candidates for October 5 polls | Mint - Mint
Videocon d2h lists on Nasdaq | Mint - Mint
Apni Party's Altaf Bukhari, BJP's Devender Rana among 3 richest candidates in Jammu and Kashmir assembly poll fray | Mint - Mint
Dr. Reddy's Labs ADR Sees RS Rating Rise To 72 - Investor's Business Daily
Dr. Reddy’s Empowers Employees with Stock Options - TipRanks
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited - Business Wire
Mondrian Investment Partners LTD Has $11.56 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr. Reddy's Laboratories Share Price Today Live Updates: Dr. Reddy's Laboratories Sees 1.48% Decline, Cu... - The Economic Times
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories Sees Minor Price Dip Amidst ... - The Economic Times
US FDA closes inspection of Dr Reddy’s API unit - BusinessLine
Mexico Antiviral Drugs Market Size & Outlook, 2022-2030 - Grand View Research
The United States Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Latin America Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? - Investor's Business Daily
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
Volume Updates: Dr. Reddy's Laboratories Sees Significant Surge in Trading Volume - The Economic Times
Dr. Reddy’s Approves Employee Share Allotment - TipRanks
Stocks in news: Interarch, Dr Reddy's Labs, Ceigall, ONGC, Akums, Trent, Zydus Life & Uno Minda - Business Today
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug - Yahoo Finance
Depository receipts regime fails to take off due to Sebi concerns | Mint - Mint
China Biosimilars Market Size & Outlook, 2020-2027 - Grand View Research
Buy or sell: Dr Reddy's to HCL Tech, Vaishali Parekh recommends three stocks to buy today — 14 August | Stock Market News - Mint
Dr Reddy's Labs shares drop after US FDA gives VIA tag to Vizag facilities - Business Standard
Form N-CSRS Northern Lights Fund For: May 31 - StreetInsider.com
1:5 Split: Mega Pharma Makes Big Acquisition Update; LIC's 92,10,387 Shares To Become 4,60,51,935 Shares; BUY? - Goodreturns
Lenovo Accelerates ‘Smarter AI for All’ with Databricks Collaboration - Business Wire
Dr Reddy's Laboratories Ltd (RDY) Q1 2025 Earnings Call Transcri - GuruFocus.com
Dr. Reddy’s Earnings: Continued Strength in Execution Lifts Valuation, but Shares Still Pricey - Morningstar
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
1:5 Split, First In 25 Yrs: Rs 6,840 Pharma Major Dr Reddy's To Split Into 5 Shares; BUY For Rs 8,010 Target - Goodreturns
Q1 results today: ICICI Bank, Dr Reddy's Lab, MCX, Finolex Industries, Punjab National Bank & more to report earnings | Company Business News - Mint
Nestle India And Dr Reddys Laboratories Form Joint Venture Company - NDTV Profit
Dr Reddy’s to Consider Stock Split on 27 July, Shares Trading Flat - EquityPandit
Wipro vs TCS vs Infosys vs HCL Tech: Which IT stock to buy after Q1 results 2024? | Stock Market News - Mint
Nifty 50, Sensex today: What to expect from Indian stock market in trade on July 19 | Stock Market News - Mint
Infosys share price in focus as ADR jumps over 8% after Q1 results beat estimates | Stock Market News - Mint
GIFT City: Expert panel calls for a new framework for dispute resolution at the IFSC | Today News - Mint
Dr. Reddy’s Laboratories Ltd. ADR Inc. (RDY) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Infosys Q1 results tomorrow: 4 things from revenue growth to deal wins to be watched out for in the earnings show | Stock Market News - Mint
Australia Peptide And Oligonucleotide CDMO Market Size & Outlook, 2030 - Grand View Research
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):